Effect of Body Weight on Risk-Benefit and Dosing Regimen Recommendation of Secukinumab for the Treatment of Moderate to Severe Plaque Psoriasis.

Subjects with higher body weight typically have higher drug clearance and lower drug concentrations when treated with monoclonal antibody products.(1,2) This is especially important for monoclonal antibody products used in the treatment of psoriasis because psoriasis patients typically have higher mean body weight than the general population.(3,4) Here we describe the exposure-response analyses performed during the approval of secukinumab (Cosentyx).